Effect of probiotics on colorectal cancer in clinical trials

Development of probiotic product prototype for prevention and delay progression of colon cancer and clinical trial study (2nd year)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220408001

Enrollment

Registered

2022-04-08

Start date

2022-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Ten subjects receive probiotic product contained 10 million CFU in viable form 3 times a day for 6 months,Ten subjects receive probiotic product contained 10 million CFU in non viable form 3 tim

Active Comparator Dietary Supplement,Active Comparator Dietary Supplement,Placebo Comparator Dietary Supplement

probiotic products in viable form,probiotic products in non viable form,Control

Eligibility

Sex/Gender

All

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. have been diagnosed as having colorectal cancer stage 2-3 2. 30 subjects were included

Exclusion criteria

Exclusion criteria: 1. any other systemic diseases e.g. diabetes, myocardial infarction kidney diseases 2. immuno-compromised host 3. allergy for cow milk 4. having a habit for regular taking fermented food

Design outcomes

Primary

Measure	Time frame
reduceing of number of pathogens in gut at 6 months after intervention number of pathogens / Anova	—

Secondary

Measure	Time frame
reducing of pro-inflammatory cytokines in serum at 6 months after intervention pro-inflammatory cytokines / ANOVA	—

Countries

Thailand

Contacts

Public ContactRawee Teanpaisan

Prince of Songkla University

rawee.t@psu.ac.th66896555836

Outcome results